GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (FRA:0T2) » Definitions » Cyclically Adjusted Book per Share

Traws Pharma (FRA:0T2) Cyclically Adjusted Book per Share : €592.93 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Traws Pharma's adjusted book value per share for the three months ended in Dec. 2023 was €0.466. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €592.93 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Traws Pharma's average Cyclically Adjusted Book Growth Rate was -7.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-05-15), Traws Pharma's current stock price is €0.59. Traws Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was €592.93. Traws Pharma's Cyclically Adjusted PB Ratio of today is 0.00.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Traws Pharma was 0.40. The lowest was 0.10. And the median was 0.20.


Traws Pharma Cyclically Adjusted Book per Share Historical Data

The historical data trend for Traws Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Cyclically Adjusted Book per Share Chart

Traws Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 5.38 682.23 592.93

Traws Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 682.23 601.14 1,074.08 904.84 592.93

Competitive Comparison of Traws Pharma's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Traws Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Cyclically Adjusted PB Ratio falls into.



Traws Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Traws Pharma's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.466/129.4194*129.4194
=0.466

Current CPI (Dec. 2023) = 129.4194.

Traws Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201403 4,803.534 99.695 6,235.755
201406 3,708.204 100.560 4,772.434
201409 2,839.108 100.428 3,658.705
201412 1,911.813 99.070 2,497.491
201503 1,125.803 99.621 1,462.549
201506 345.445 100.684 444.036
201509 284.995 100.392 367.400
201512 811.749 99.792 1,052.746
201603 441.544 100.470 568.768
201606 88.916 101.688 113.164
201609 272.437 101.861 346.145
201612 135.619 101.863 172.308
201703 -110.000 102.862 -138.400
201706 -7.880 103.349 -9.868
201709 -132.389 104.136 -164.533
201712 -206.371 104.011 -256.784
201803 -72.377 105.290 -88.964
201806 36.013 106.317 43.839
201809 24.603 106.507 29.896
201812 12.517 105.998 15.283
201903 -3.458 107.251 -4.173
201906 -10.060 108.070 -12.047
201909 -10.037 108.329 -11.991
201912 1.406 108.420 1.678
202003 1.731 108.902 2.057
202006 1.195 108.767 1.422
202009 0.843 109.815 0.993
202012 0.409 109.897 0.482
202103 1.978 111.754 2.291
202106 1.735 114.631 1.959
202109 2.021 115.734 2.260
202112 1.953 117.630 2.149
202203 1.838 121.301 1.961
202206 1.742 125.017 1.803
202209 1.611 125.227 1.665
202212 1.277 125.222 1.320
202303 1.019 127.348 1.036
202306 0.832 128.729 0.836
202309 0.648 129.860 0.646
202312 0.466 129.419 0.466

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Traws Pharma  (FRA:0T2) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Traws Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.59/592.93
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Traws Pharma was 0.40. The lowest was 0.10. And the median was 0.20.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Traws Pharma Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Traws Pharma (FRA:0T2) Business Description

Industry
Traded in Other Exchanges
Address
12 Penns Trail, Newtown, PA, USA, 18940
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Traws Pharma (FRA:0T2) Headlines

No Headlines